Cell-Derived Vaccine Against Bovine Leukaemia Virus Infection

Zentralblatt für Veterinärmedizin. Reihe B. Journal of veterinary medicine. Series B 01/1989; 35(10):736-46. DOI: 10.1111/j.1439-0450.1988.tb00553.x
Source: PubMed


The idea was tested whether live heterologous mammalian cells producing env gene glycoproteins and main structural protein p 24 of bovine leukaemia virus (BLV) could serve as a vaccination material in cattle to prevent induction of bovine leukaemia. A clone of ovine virus-non-producing cells NP-2 was found to express only a part of viral products. The NP-2 cells inoculated into rats induced antibody response directed against envelope glycoproteins of BLV. The antibodies neutralized the infectivity of BLV as determined by the VSV/BLV pseudotype neutralization test. Similar results were obtained by vaccination of cattle with these cells. In vaccinated animals antibodies against env gene products were detected. The antibody level increased after revaccination at any time during the observation period of 24 months. The antibodies neutralized BLV. A group of young heifers after repeated vaccination was challenged with virus or/and by virus-producing cells. The response to BLV infection was followed by syncytia formation on indicator CC 81 cells after co-cultivation with white blood cells from tested animals. While the unvaccinated control animal, two months after virus challenge, was found to be infected, all vaccinated animals were protected. Thus, live heterologous cells producing env gene products and p24 of BLV, can protect cattle against bovine leukaemia BLV-induced leukaemia.ZusammenfassungImpfstoff zellulärer Abstammung gegen Infektion mit bovinen LeukosevirenDie vorliegende Arbeit beschreibt die Verwendung von ovinen Zellkulturen als Impfstoff gegen bovine Leukoseviren (BLV). Dabei wird die bereits 1987 vorgestellte Zellinie NP-2 verwendet, die zwar das virale Hüll-(env-)Protein, aber keine Viruspartikel produziert. Die Stimulierung der Bildung neutralisierender Antikörper in Ratten wurde mit dem VSV/BLV-Pseudotyp-Neutralisationstest bestimmt. Anschließend wurden Rinder mit diesen heterologen Zellen immunisiert und der Titeranstieg nach Revakzination über 24 Monate verfolgt. Bei einigen Tieren wurde nach der ersten Revakzination ein Virusbelastungstest durchgeführt. In keinem der geimpften und anschließend belasteten Tiere konnte nach der gesamten Untersuchungsdauer vermehrungsfähiges Virus nachgewiesen werden.

Download full-text


Available from: Cestmir Altaner,
  • Source
    • "The proteins were separated by sodium dodecyl sulfate-polyacrylamido gel electrophoresis as described in detail previously [2]. The proteins were transferred to nitrocellulose membranes using a semi-dry electroblotter as de­ scribed by ANDERS iíN [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A capture monoclonal antibody-based assay has been established for detecting the p24 core protein and the gp51 envelope glycoprotein of bovine leukemia virus (BLV). This assay is rapid, highly sensitive and specific. Viral antigens in test samples were identified using mouse monoclonal antibody-coated or microtiter plates by adding labeled monoclonal antibodies with different epitope specificities. The choice of an appropriate epitope specificity for the specificity of monoclonal antibodies was important for optimal performance of the assay. Results of this assay were in agreement with the syncytia induction assay routinely used for detecting BLV production by cells in vitro. The sensitivity of monoclonal antibody assay was 0.5 ng/ml for p24 and 1.25 ng/ml for gp51, respectively. The specificity was demonstrated by immunoblotting. The assay can be performed in a few hours, is simple, and is comparable with more time-consuming assays with regard to sensitivity and specificity.
    Neoplasma 02/1991; 38(6):625-31. · 1.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bovine leukemia virus (BLV) is a retrovirus closely related to the human T-lymphotropic virus type 1 (HTLV-1). BLV is a major animal health problem worldwide causing important economic losses. A series of attempts were developed to reduce prevalence, chiefly by eradication of infected cattle, segregation of BLV-free animals and vaccination. Although having been instrumental in regions such as the EU, these strategies were unsuccessful elsewhere mainly due to economic costs, management restrictions and lack of an efficient vaccine. This review, which summarizes the different attempts previously developed to decrease seroprevalence of BLV, may be informative for management of HTLV-1 infection. We also propose a new approach based on competitive infection with virus deletants aiming at reducing proviral loads.
    Viruses 07/2011; 3(7):1210-48. DOI:10.3390/v3071210 · 3.35 Impact Factor